High Evidence
Research Overview
Mazdutide Research for Obesity
An evidence-based overview of research examining Mazdutide in the context of obesity. This page synthesizes findings from peer-reviewed literature.
Research Summary
Mazdutide has robust Phase 3 evidence for obesity treatment. The GLORY-1 trial (N=610) demonstrated 14.3% weight loss at 48 weeks with 6mg dosing, with 64% of participants achieving ≥10% weight loss. NMPA approved in China for weight management in June 2025.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Obesity
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Mazdutide may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.